Skip to Content

Advancements and Emerging Challenges in HER2-Low Treatment

In this MEDtalk, Paolo Tarantino, from the Dana-Farber Cancer Institute, highlights the transformative potential of novel antibody conjugates in treating HER2-positive and HER2-low breast cancer. Through recent trials, Tarantino challenges traditional assumptions about HER2 expression and demonstrates promising outcomes for HER2-low tumours.

Paolo Tarantino

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top